Nestlé faces heat over unhealthy products, plans to revamp portfolio
Category: #headlines  By Nikita Chaurasia  Date: 2021-06-01
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Nestlé faces heat over unhealthy products, plans to revamp portfolio

Swiss multinational food and beverage conglomerate, Nestlé S.A., is reportedly planning to upgrade its health and nutrition policy after an internal document revealed that the company described a major portion of its food products as ‘unhealthy’.

According to sources, the internal document circulated among top management early this year states that over 60% of Nestlé’s mainstream food and beverage offerings could not be conferred as ‘healthy’ in reference to the ‘recognized definition of health’.

About 70% of the company’s food products failed to meet the mark under Australia’s Health Star Rating system, alongside 96% of its beverages, barring pure coffee. In addition to that, nearly 99% of its ice cream and confectionary portfolio came up short on the yardstick.

For the record, the assessment did not cover Nestlé’s complete portfolio, as categories like pet food, medical nutrition, coffee and infant formula were exempted from the evaluation.

Nestlé said that it has launched thousands of products for families and kids that meet external nutrition benchmarks, emphasizing that a healthy diet involves finding balance between wellbeing and satisfaction, while including a moderate consumption of some indulgent foods.

The company also expressed that its primary objective to continue making its product portfolio tastier and healthier has remained unchanged. As a testament, the food giant has been working on an organization-wide project to upgrade its nutrition and health strategy and is analyzing its entire portfolio to ensure that the products help meet people’s nutritional requirements.

Nestlé also revealed that it has reduced sugar and sodium content in its products by over 14-15% in the past seven years and is taking efforts to develop products which are healthier.

Meanwhile, Nestlé India intends to provide families of employees who succumbed to Covid-19, with a two-year base salary with gratuity, pension, and other applicable benefits, along with educational support for children and reimbursement of critical hospital expenses of impacted family members, cited credible sources.

Source Links –

https://whbl.com/2021/05/31/nestle-under-fire-over-unhealthy-products-working-on-new-strategy/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Coretec Group, Eindhoven University join hands for research works

Coretec Group, Eindhoven University join hands for research works

By Nikita Chaurasia

U.S.-based new silicon products pioneer Coretec Group Inc. has reportedly entered into a research partnership with Eindhoven University of Technology (TU/e), which is among the leading 50 universities in engineering and technology globally as per QS ...

FedEx partners with Nuro to develop autonomous package delivery systems

FedEx partners with Nuro to develop autonomous package delivery systems

By Nikita Chaurasia

FedEx Corporation and robotics startup Nuro have reportedly signed a multi-year agreement to develop and test last-mile delivery using autonomous vehicles. The American multinational delivery giant will be using its Houston facility for the pilot pro...

Breckenridge Pharmaceutical receives FDA approval for anti-cancer drug

Breckenridge Pharmaceutical receives FDA approval for anti-cancer drug

By Nikita Chaurasia

According to reliable sources, Natco Pharma’s marketing partner Breckenridge Pharmaceutical Inc. has obtained approval from U.S. Food and Drug Administration (USFDA), for its anti-cancer drug Carfilzomib Vials. For the record, Carfilzomib Vial...